Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2026

Q1 2026 biggest moves
  • SNDXSNDX

    Syndax Pharmaceuticals

    New

    1.0% of portfolio

  • DNTHDNTH

    Dianthus Therapeutics

    New

    1.0% of portfolio

  • PFEPFE

    Pfizer

    New

    1.0% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    Cut 48%

    now 0.9% of portfolio

115 changes in all

Top Holdings82 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

17.2M$1.8B20.8%——
19 qtrssince 2021-Q3
Unchanged
0
306.9M$505.4M6.0%——
2 qtrssince 2025-Q4
Unchanged
0
COGT

Cogent Biosciences, Inc.

9M$348.1M4.1%$12.67+203.81%
22 qtrssince 2020-Q4
Unchanged
0
PRAX

Praxis Precision Medicines, Inc.

963,351$310.4M3.7%$74.95+329.86%
5 qtrssince 2025-Q1
Increased
61
VTRS

Viatris Inc.

20.2M$273M3.2%$11.15+19.38%
22 qtrssince 2020-Q4
Unchanged
0
UTHR

United Therapeutics Corporation

457,000$271M3.2%$318.01+86.46%
5 qtrssince 2025-Q1
Increased
61
RVMD

Revolution Medicines, Inc.

2.3M$223.4M2.6%$29.54+229.25%
25 qtrssince 2020-Q1
Decreased
0
70M$209.4M2.5%——
8 qtrssince 2024-Q2
Unchanged
0
200M$207.2M2.4%——
1 qtr
New
79
CELC

Celcuity Inc.

1.7M$195.6M2.3%$78.20+45.97%
3 qtrssince 2025-Q3
Unchanged
0
CNC

Centene Corporation

5.9M$193.7M2.3%$46.26-29.22%
26 qtrssince 2019-Q4
Decreased
0
LRMR

Larimar Therapeutics, Inc.

35.6M$160.2M1.9%$5.44-17.30%
24 qtrssince 2020-Q2
Increased
55
BKD

Brookdale Senior Living Inc.

11.6M$159.2M1.9%$4.41+210.17%
26 qtrssince 2019-Q4
Unchanged
0
VERA

Vera Therapeutics, Inc.

3.7M$149.7M1.8%$26.87+49.73%
5 qtrssince 2025-Q1
Decreased
0
IONS

Ionis Pharmaceuticals, Inc.

2M$148.7M1.8%$65.42+14.78%
3 qtrssince 2025-Q3
Unchanged
0
BCRX

BioCryst Pharmaceuticals, Inc.

15M$143.2M1.7%$7.42+28.32%
13 qtrssince 2023-Q1
Increased
50
INSP

Inspire Medical Systems, Inc.

2.7M$139.4M1.6%$70.11-26.43%
4 qtrssince 2025-Q2
Increased
73
LEGN
LEGN
ADR

Legend Biotech Corporation

7.7M$139.1M1.6%$25.57-29.25%
6 qtrssince 2024-Q4
Increased
60
AHCO

AdaptHealth Corp.

11.5M$136.6M1.6%$16.65-28.55%
26 qtrssince 2019-Q4
Unchanged
0
NAMS

NewAmsterdam Pharma Company N.V.

4.3M$136.5M1.6%$23.84+34.26%
9 qtrssince 2024-Q1
Increased
49
$8.5B
AUM
82
Positions
Q1 2026
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2024-Q4$5,280,006,191-21.1092279632%
2025-Q1$5,064,779,427-4.07625969013%
2025-Q2$5,509,809,2648.78675652937%
2025-Q3$6,550,740,15118.8923216236%
2025-Q4$7,830,165,97019.5310116034%
2026-Q1$8,476,379,7168.25287418525%
Activity profile
$ moved · Q1'26
New42%Increased19%Decreased16%Exited23%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.0 years
<1Q11%1-4Q4%1-2Y4%2Y+82%

Deerfield Management Company, L.P. manages $8.5B across 82 positions as of Q1 2026. Top holdings: NUVL (20.8%), BROOKDALE SR LIVING INC (6.0%), COGT (4.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$8B
NUVL20.85%
BROOKDALE SR5.96%
COGT4.11%
PRAX3.66%
VTRS3.22%
UTHR3.20%
RVMD2.64%
MIRUM PHARMA2.47%
ARROWHEAD PH2.44%
CELC2.31%
Other2.29%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used